Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six brokerages that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $7.00.
ADPT has been the topic of several analyst reports. JPMorgan Chase & Co. raised their target price on Adaptive Biotechnologies from $5.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. BTIG Research raised their target price on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd.
View Our Latest Stock Analysis on Adaptive Biotechnologies
Institutional Investors Weigh In On Adaptive Biotechnologies
Adaptive Biotechnologies Stock Performance
Shares of NASDAQ:ADPT opened at $4.68 on Wednesday. The company has a market cap of $689.68 million, a P/E ratio of -3.14 and a beta of 1.44. Adaptive Biotechnologies has a one year low of $2.28 and a one year high of $5.80. The business’s 50-day simple moving average is $4.69 and its 200 day simple moving average is $3.91.
Adaptive Biotechnologies (NASDAQ:ADPT – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.02. The business had revenue of $43.19 million for the quarter, compared to the consensus estimate of $38.63 million. Adaptive Biotechnologies had a negative return on equity of 60.99% and a negative net margin of 126.49%. The company’s revenue was down 11.7% on a year-over-year basis. During the same period last year, the business posted ($0.33) EPS. Analysts predict that Adaptive Biotechnologies will post -1.19 earnings per share for the current year.
About Adaptive Biotechnologies
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.
Read More
- Five stocks we like better than Adaptive Biotechnologies
- How to Most Effectively Use the MarketBeat Earnings Screener
- Is Spotify Stock Poised to Soar? Options Traders Think So
- 5 discounted opportunities for dividend growth investors
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- Stock Market Upgrades: What Are They?
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.